Researchers discover new class of compound that targets cancer stem cells

Many cancer therapies, in addition to producing numerous side effects, fail to achieve complete tumour remission, partly due to the presence of cancer stem cells, which are difficult to eradicate.

Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch

VABYSMO gained FDA approval in January 2022. Credit: Jo Panuwat D via Shutterstock. Last week, Roche released promising first-quarter (Q1) 2024 sales figures for VABYSMO,

May 1, 2024

Air pollution spurs inflammation in heart failure patients

A new study by heart researchers at Intermountain Health in Salt Lake City finds that patients with heart disease, specifically those with heart failure, are

November 18, 2024

Risk of Contrast Media Causing Acute Kidney Injury Is Overblown, Study Finds

PHILADELPHIA — The myth that certain patients need to avoid iodinated contrast media (ICM) for fear of acute kidney injury (AKI) persists despite evidence that

October 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.